Internal Reference Number: FOI_7978
Date Request Received: 04/06/2024 00:00:00
Date Request Replied To: 26/06/2024 00:00:00
This response was sent via: By Email
Request Summary: Oncology Breast Cancer
Request Category: Companies
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Aromatase Inhibitor as a single agent • Atezolizumab • Capecitabine as a single agent • Carboplatin + Paclitaxel • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Transtuzumab deruxtecan • Trastuzumab as a single agent or in combination • Trastuzumab emtansine • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 16 • Abemaciclib + Fulvestrant 5 • Alpelisib + Fulvestrant 0 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide 0 • Aromatase Inhibitor as a single agent - unable to answer • Atezolizumab 0 • Capecitabine as a single agent 15 • Carboplatin + Paclitaxel <5 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane <5 • Fulvestrant as a single agent 0 • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 32 • Palbociclib + Fulvestrant 7 • Parp Inhibitors (Olaparib/Talazoparib) <5 • Pembrolizumab <5 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 13 • Ribociclib + Fulvestrant <5 • Sacituzumab Govitecan <5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent <5 • Transtuzumab deruxtecan 6 • Trastuzumab as a single agent or in combination 43 • Trastuzumab emtansine <5 • Any other active systemic anti-cancer therapy 14 | |
| Question Number 2: If breast cancer is not treated at or within the Trust, where are patients referred? | |
| Answer To Question 2: N/A - patients are treated in this Trust. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
